VIR | Ticker Profile - Titan Protect

VIR

Vir Biotechnology, Inc.

Healthcare · Biotechnology · NMS

$8.65

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.5B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.96

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-47.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.00

+131% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

https://www.vir.bio

Country: United States Employees: 367 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.326

Positive but modest risk-adjusted returns

Kelly Fraction

0.0125

Marginal edge — very small allocation suggested

Calmar Ratio

-0.042

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-2.8%

Historical annualised return based on price data

Max Drawdown

-66.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.70

Significantly more volatile than the market

52W High

$11.66

26% below the year high

52W Low

$4.16

108% above the year low

Avg Volume

2,204,078

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.1%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.13

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

11.76

Heavy leverage — higher financial risk if revenues decline

Current Ratio

7.11

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

6.52

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

459,241.4%

Profit from core operations before interest and tax

Free Cash Flow

$-214,927,632

Negative — the business is spending more than it generates

Revenue (TTM)

$65M

Total revenue over the last 12 months

Net Income

$-442,716,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$30.00

Target Median

$20.00

Target Low

$16.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go